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Hepatitis C virus, human immunodeficiency virus, and hepatitis B virus are chronic viral
infections that cause considerable morbidity and mortality throughout the world. In the
decades following the identification and sequencing of these viruses, in vitro experiments
demonstrated that heme oxygenase-1, its oxidative products, and related compounds of
the heme oxygenase system inhibit replication of all 3 viruses. The purpose of this review
is to critically evaluate and summarize the seminal studies that described and characterized
this remarkable behavior. It will also discuss more recent work that discovered the antiviral
mechanisms and target sites of these unique antiviral agents. In spite of the fact that these
viruses are diverse pathogens with quite profound differences in structure and life cycle,
it is significant that heme and related compounds show striking similarity for viral target
sites across all three species. Collectively, these findings strongly indicate that we should
move forward and develop heme and related tetrapyrroles into versatile antiviral agents
that could be used therapeutically in patients with single or multiple viral infections.
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INTRODUCTION
Hepatitis C virus (HCV), Hepatitis B virus (HBV), and Human
immunodeficiency virus (HIV) are three of the most common
chronic viral infections worldwide. All of these viruses share
common risk factors and modes of transmission including sex-
ual, human blood product transfusion, and intravenous drug use
(Koziel and Peters, 2007). In the decades following discovery and
sequencing of all three viruses, there has been a constant medical
need to update treatment regimens and employ new and more
versatile antiviral agents. This review will focus on in vitro and
molecular studies that have evaluated metalloporphyrins, specif-
ically heme, and related derivatives, for their virucidal activity
against the three viruses. What are emerging from these collective
works are not only fascinating pictures of multiple viral targets
to explain the antiviral activities of these metalloporphyrins, but
there is also a promise that these compounds can be developed
successfully into powerful, yet versatile antiviral agents.
THE HEME AND HEME OXYGENASE SYSTEMS
Heme (iron protoporphyrin IX) is the most common metal-
loporphyrin (MP) in eukaryotic cells and is essential for life.
Heme is constructed from a highly conserved sequence of eight
enzymatic reactions that sequentially link precursors into four
pyrrole precursor rings to form the tetrapyrrole, protoporphyrin
IX. In the final anabolic step, ferrous iron is inserted by the
enzyme ferrochelatase to form heme or iron protoporphyrin IX
(Figure 1; Heinemann et al., 2008). Heme is regularly complexed
Abbreviations: BR, bilirubin; BV, biliverdin; BVR, biliverdin reductase; FL, full
length; HBV, hepatitis B virus; HCV, hepatitis C virus; HIV, human immunode-
ficiency virus; HO, heme oxygenase; MP, metalloporphyrin; MPP, metalloproto-
porphyrin; NS, non-structural; RT-PCR, reverse transcriptase polymerase chain
reaction.
into respiratory proteins such as hemoglobin and myoglobin to
form a vital oxygen carrying and delivery platform. As a prosthetic
group heme also performs essential activities for electron transfer
and oxidation (Gray and Winkler, 1996). Because of the critical
nature of all these basic activities, it is not surprising that virtually
all steps of heme synthesis and degradation are tightly regulated
with oxidative balance and many signaling pathways (Mense and
Zhang, 2006).
Since the 1970s, commercial preparations of heme (Hemin
and Panhematin), have been approved by the FDA for use in
patients with acute porphyria. In addition to iron, natural met-
alloprotoporphyrins (MPP) and a variety of synthetic MP can
complex other metals such as zinc, copper, cobalt, magnesium,
manganese, tin, nickel, or chromium. Naturally occurring MPs
serve as necessary co-factors for numerous oxygenases, peroxi-
dases, and catalases. ZnPP, formed naturally during times of iron
deficiency, is an excellent serum marker for iron deficiency ane-
mia (Labbe, 1992) and has generated therapeutic interest for the
treatment of jaundice of the newborn.
Initial catalysis of heme occurs via oxidation with heme oxidase
(HO; Figure 2). The major isoforms of HO are HO-1 and HO-2.
The role of HO-3 is not clear and is considered a pseudo transcript
of HO-2 (Cruse and Maines,1988; McCoubrey et al., 1997; Hayashi
et al., 2004). HO-1 and HO-2 perform similar net enzymatic func-
tions, yet only HO-1 is usually induced in response to cellular
stressors such as hypoxia, cytotoxic agents, and infection (Immen-
schuh and Ramadori, 2000). HO opens the porphyrin ring of heme
which is rate limiting for heme catabolism, and liberates equimo-
lar ratios of Fe+2, carbon monoxide, and the linear tetrapyrrole
biliverdin (BV). The reaction uses 3 mol of oxygen and reduc-
ing equivalents from NADPH: cytochrome P-450 (cytochrome c)
reductase. BV is then rapidly converted to bilirubin (BR) by BV
reductase (BVR). The entire sequence of heme oxidation and BV
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FIGURE 1 | Representative porphyrin structures. (A) pyrrole ring, (B) porphyrin ring, (C) protoporphyrin IX, and (D) Heme, iron protoporphyrin IX.
FIGURE 2 | Heme oxygenase and biliverdin reductase enzymes.
reduction likely takes place in synchrony upon a large complex of
enzymes and co-factors that include HO, BVR, and NADPH (Ryter
et al., 2006). BR and other tetrapyrrole derivatives are ubiquitous
in nature and have a wide variety of functions in animals (McDon-
agh, 2001). Both HO-1 and BVR are highly inducible enzymes and
respond to signaling and feedback in numerous cellular systems
(Ryter et al., 2006; Kapitulnik and Maines, 2009). HO-1 induction
provides important protection from oxidative stress and cellular
damage (Abraham et al., 1995; Lee et al., 1996; Guo et al., 2001).
Over the last two decades it is also becoming apparent that the
precursors and catabolic products of the heme oxygenase system
are capable of antimicrobial and antiviral activities. Of importance
here, HO-1 induction or overexpression promotes a wide range of
antiviral activities for the major viral pathogens discussed in this
review: HIV, HBV, and HCV (Devadas and Dhawan, 2006; Protzer
et al., 2007; Shan et al., 2007; Zhu et al., 2008).
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GENERAL CONSIDERATIONS OF VIRUCIDAL ACTIVITIES OF
HEME AND RELATED COMPOUNDS
Heme and structurally related MPs have actually generated interest
as antimicrobials and antiviral agents for some time (Stojiljkovic
et al., 2001). Porphyrins induce antiviral reactions through both
non-specific and specific interactions with either host or virus
which typically interfere with the viral life cycle. Typical non-
specific interactions include activities such as hydrophobic binding
of the porphyrin with host cell membranes or viral envelope that
inhibit viral binding and cellular entry. Generalized antiviral activ-
ities reflect the diversity of porphyrin structure as well as chemical
complexity and versatility. Photoactive MPs absorb photons and
partition into membranes to where they can exert a virucidal effect,
especially with enveloped viruses as noted below.
In contrast, specific interactions of natural MPs appear highly
dependent on structure and reflect the fact that the primary func-
tion of heme and similar MPs usually behave as crucial co-factors
in specific oxidase and peroxidase reactions. Consequently, an
emerging pattern suggests that natural MPs show more affinity
and specificity for viral inhibition because they are the preferred
cofactor for established cellular reactions that are metabolically
protective for cellular stress which may also severely reduce viral
fitness. This assertion is clearly tentative, however, and has not
been formally studied.
Recently, a group of alkylated porphyrins was reported to
inhibit hepadnaviruses, flaviviruses, filoviruses, and arena viruses
(Guo et al., 2011). The antiviral effects of these compounds,
or chlorophyllides (an alkylated porphyrin containing copper
charged at neutral ph), were discovered by screening over 2,000
compounds for their ability to decrease HBV DNA in cultured
cells. A derivative of chlorophyllide, the metal free chlorin e6a,was
the most active compound of this group. Antiviral activity for
other viruses such as HCV, HIV-1, Dengue (DENV-2), Marburg
virus (MARV), Junin viruses (JUNV), and herpes simplex (HSV-
1) was also shown. Activity had high EC50s in the low micromolar
and nanomolar range for some viruses such as DENV and was
selective for enveloped viruses. Non-enveloped viruses such as
encephalomyocarditis (EMCV) and adenovirus (Ad) were highly
resistant. The active porphyrin compounds caused disruption and
dissociation of viral envelope proteins as assessed in a particle gel
assay. These studies suggest use for these compounds as generalized
virucidal agents for enveloped viruses.
Alternatively, an interesting antiviral application of some pho-
toactive MPs has been studied for non-enveloped viruses such
as Hepatitis A virus (HAV). HAV is a small picornavirus that is
orally transmitted from fecal contaminated water and food. Like
all picornaviruses (the family includes notable human pathogens
such as polioviruses, enteroviruses, and rhinoviruses) the non-
envelope structure of HAV presents challenges for prevention of
infection because of its small size and resistance to inactivation.
These viruses are highly resistant to common bacterial filtration
techniques and the protein capsid renders the virus more resistant
to chemical disinfection (Lemon et al., 1994). Casteel et al. (2004)
showed that synthetic porphyrins could photo-inactivate HAV in
plasma and other body fluids. Consequently, synthetic porphyrins
may offer an effective and relatively safe approach to disinfec-
tion of non-enveloped viruses in various types of aqueous media.
Potentially, this remarkable property could widely influence the
epidemiology and pathogenesis of a variety of common pathogens
that cause considerable morbidity and mortality worldwide.
Song et al. (1997) assessed the anti-HIV properties of various
water-soluble polysulfonated and polycarboxylated porphyrins
and their metal (Mn, Fe, and Ni) derivatives against HIV-1, HIV-
2, and simian immunodeficiency virus infection in MOLT4 target
cells. Some of these compounds were potent inhibitors of HIV
infection and they likely interfere with the binding of HIV pro-
tein gp120 to the CD4 cellular receptor. Specific antibody studies
demonstrated that the porphyrins directly bound to the gp 120
protein to inhibit formation and uptake of gp 120 and CD4+ T
cell receptor binding complex. Interestingly, the gp 120 protein
was also the probable binding site of a group of boronated por-
phyrins and other related MPs that were reported to bind gp120
and inhibit infection of CD4+ T cell line MT-2 (Debnath et al.,
1994, 1999).
The antiviral activities of some more specialized synthetic
porphyrins and derivatives against HCV have also been studied
recently (Cheng et al., 2010). These workers evaluated structure-
activity relationships of synthetic tetraphenylporphyrins and their
anti-HCV properties as a proof-of- concept model for the devel-
opment of proteomimetics in HCV drug discovery. Nanomolar
levels of a biphenyl porphyrin derivative were noted to be the most
potent inhibitor of full length Con1 replicons (Blight et al., 2002)
but were less active for genotype 2a (JFH-1) subgenomic replicons
(Kato et al., 2003). Furthermore, the porphyrin showed synergis-
tic antiviral activity when incubated with replicons together with a
known HCV protease inhibitor BILN 2061 as well as the antiviral
cytokine α-interferon-2a. While the cellular targets for the por-
phyrin derivatives are not yet clear, these studies demonstrate that
the tetraphenylporphyrin backbone is a useful scaffold on which
to hang a variety of chemical groups and define structure-function
relationships for additional antiviral development.
DIRECT EFFECTS OF HEME AND RELATED COMPOUNDS
Direct interactions of heme and related MPs are important med-
ically for the development of new and improved antiviral agents
against HIV, HBV, and HCV in addition to other human pathogens
that cause persistent infection and chronic disease. Viral targets
might include any of the key steps in a virus’ life cycle such as
entry, replication, assembly, and exit from the host cell. Alter-
natively, interactions of MP that enhance pathogen recognition
and immune response pathways would be expected to decrease
viral fitness and replication mechanisms. In this regard, heme and
related natural compounds have recently been shown to possess
astonishingly specific antiviral protease and polymerase activi-
ties for both human hepatotrophic and HIV viruses. As discussed
below, an emerging pattern demonstrates novel actions of heme
that influence not only viral replication, but immune recogni-
tion, inflammation, primary interferon responses, apoptosis, and
oxidative defense mechanisms.
ACTIONS ON SPECIFIC VIRUSES
HEPATITIS C VIRUS
Hepatitis C virus is a small enveloped RNA virus and occupies
a single genus of Hepacivirus of the Flaviviridae family. This
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family also includes such human pathogens as yellow fever and
dengue. HCV has a plus-stranded RNA genome with a single long
open-reading frame that is translated into a large polyprotein,
then processed by host and viral proteases (Lindenbach and Rice,
2005). The non-structural (NS) proteins NS3/4A protease, NS5B
RNA dependent RNA polymerase (RdRp) and the NS5A protein,
necessary for replication, have been the targets of intense research
efforts to develop new antiviral drugs (Soriano et al., 2009). The
ability to study the HCV life cycle and develop anti-HCV agents
was initially hampered for nearly a decade by the inability to grow
and pass the virus in cell culture or small animal models. How-
ever, viral replicon models began to appear by 1999 (Lohmann
et al., 1999; Pietschmann et al., 2001; Blight et al., 2002) and these
constructs enabled high throughput in vitro testing for a wide vari-
ety of potential antiviral drugs. In addition to replicons, defined
infectious strains (Cai et al., 2005; Wakita et al., 2005) and patient
wild type viruses (Castet et al., 2002; Gondeau et al., 2009) have
been passed in primary hepatocytes and other permissive cell lines.
Recently, reliable chimeric mouse-human models for in vivo test-
ing of antiviral activity have also been introduced (Bissig et al.,
2007, 2010; de Jong et al., 2010; Washburn et al., 2011).
DIRECT ANTIVIRAL EFFECTS OF HEME AND DERIVATIVES ON
HCV
Indications that heme and its enzymatic products may interact
with HCV actually arose from assays of human liver slices col-
lected from HCV infected patients. Abdalla et al. (2004) evaluated
relative expression of oxidative defense enzymes in infected patient
liver samples as compared to uninfected control liver. HO-1 was
dramatically reduced in HCV infected liver, in contrast to other
antioxidative enzymes, catalase, CuZn and Mn super oxide dismu-
tases which all remained unchanged. Furthermore, immunohisto-
chemistry confirmed that the reduction of HO-1 expression was
limited to hepatocytes, the site of HCV replication, and not Kupf-
fer cells. Since chronic HCV infection causes hepatic inflammation
and progressive fibrosis, HO-1 downregulation was quite unex-
pected as it might be anticipated that the enzyme would be induced
as in other liver diseases (Makino et al., 2001; Bauer et al., 2003).
Moreover, in the same study, autoimmune hepatitis and chronic
HBV showed marked HO-1 upregulation in affected hepatocytes
(Abdalla et al., 2004). These findings suggested that the virus can
specifically modulate HO-1 expression although reasons for this
behavior were not apparent at the time. Nevertheless, reduction
of this important oxidative defense enzyme in the hepatocyte may
indirectly contribute to progressive oxidative injury and facilitate
fibrosis. In fact, later experiments demonstrated that overexpres-
sion of HO-1 in replicon cells promoted increased resistance to
oxidant-induced cytotoxicity (Zhu et al., 2008).
Ensuing work by a number of groups has revealed dramatic
innate anti-hepatitis C activities for heme and the oxidative prod-
ucts of the heme oxygenase system. It was first demonstrated
that iron can inhibit the HCV NS5B RdRp by high affinity
(Kd=−6µM) binding to the divalent cation binding pocket of
the polymerase (Fillebeen et al., 2005). The Kd for ferrous ion
was found to be 500 times greater than the preferred Mg+ ion.
Either divalent Mg or Mn is absolutely required for NS5B enzy-
matic activity (Ferrari et al., 1999; Bougie et al., 2003; Benzaghou
et al., 2004). Antiviral activity of free iron has been confirmed by
others (Yuasa et al., 2006; Zhu et al., 2008). However, free iron also
induces HO-1 suggesting that the virucidal activity of Fe is likely
more complicated than just binding and inactivating the poly-
merase (Hou et al., 2009). Iron would also be an unlikely choice
as a therapeutic agent for HCV since it is usually considered to
be a hepatotoxin (Ryter and Tyrrell, 2000) and it seems doubtful
whether sufficient intracellular levels of free iron might be achieved
in vivo to be useful therapeutically without causing cellular injury.
Mild iron accumulation in HCV infected human liver samples has
been correlated with more severe liver disease in some but not
all studies (Beinker et al., 1996; Kayali et al., 2005, 2007). Some
but not all earlier clinical studies with α-interferon treatment reg-
imens suggested that phlebotomy could improve viral clearance
and increase sustained virological responses to α-interferon (Di
Bisceglie et al., 2000; Fontana et al., 2000; Desai et al., 2008). Finally,
some of the experiments looking at the effects of iron on replica-
tion in vitro were actually performed using hemin to load cells
with iron instead of iron salts (Fillebeen et al., 2005, 2007). Con-
sequently the potency of free iron may have been overestimated
since more recent studies have shown that heme as well as its ini-
tial oxidation product biliverdin can also directly inhibit the HCV
NS3/4A protease (Zhu et al., 2010a).
As noted above, earlier work demonstrated that BV and biliru-
bin (BR) were able to inhibit the aspartyl protease of HIV (McPhee
et al., 1996). In contrast, HCV NS3/4A protease is serine acti-
vated with a classical common catalytic mechanism like other
members of this large class of proteolytic enzymes (Love et al.,
1996; Yan et al., 1998). Inhibition of serine activated proteases
with a tetrapyrrole appears common as a recent study demon-
strated that both BV and BR were capable of inactivating intestinal
trypsin and chymotrypsin (Qin, 2007). In this regard, Zhu et al.
(2010a) reported that BV, heme, and to a much lesser extent BR
were able to attenuate HCV replication in NS and full length
replicons in vitro. BV was found to be a potent inhibitor of recom-
binant NS3/4A protease using Fluorescence Resonance Energy
Transfer (FRET) inhibition assays in contrast to BR (Figure 3).
After testing a number of biologically relevant linear tetrapyrroles,
BV showed the lowest IC50 of all compounds tested (9.3µM)
and was considerably more potent than its reduction product,
BR (Figure 3A). Assays conducted in the presence of both BV
and AnaSpec #25346, a known commercially available inhibitor,
showed an additive effect. Lineweaver–Burk plots indicated a
mixed competitive and non-competitive inhibitory mechanism
(K i= 0.6µM and Ki′ = 1.1µM). Taken together, the kinetic
experiments suggest there is associated non-competitive pro-
tease inhibition that probably occurs in an allosteric fashion and
requires further study.
The marked difference in the avidity of BV and BR for the
HCV NS3/4A protease may be explained by differences in struc-
ture and physical chemistries of the two linear tetrapyrroles. BV
and BR have widely different secondary structures [see McDon-
agh, 2001 for review] in spite of the fact that they differ only by a
double vs. single C–C bond at the 10 “hinge” position respectively
(Figure 2). The hinge double bond restrains BV into a flat rather
fixed limited plane. In contrast, the free rotation about the hinge
single bond of BR allows internal hydrogen bonding of the COOH
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FIGURE 3 |Tetrapyrrole inhibition of HCV NS3/4A protease. (A,B)
Protease activity was determined fluorometrically (FRET assay) using
recombinant NS3/4A enzyme and various concentrations of inhibitors.
(C) Endogenous NS3/4A protease activity in microsomes of replicons
was measured using the same FRET assay but employing endogenous,
partially purified NS3/4A protease from replicon cells (Zhu et al., 2010a).
(D) Reciprocal (Lineweaver–Burk) plot of substrate concentration vs.
enzyme activity. Recombinant protease activity was determined
fluorometrically. Each point is the mean±SEM of 3–5 determinations
per point. Plot of [BV] vs. either 1/Vap or Km/V (not pictured) showed
highly significant linearity (r =0.975 and r =0.979 respectively,
p<0.005) indicating mixed inhibition of NS3/4A protease by BV
(Ki
′ = 1.1 mM and K i = 0.6 mM, respectively). 0 to the commercial
Inhibitor=NS3/4A protease competitive inhibitor, AnaSpec #25346.
Biliverdin=>99% Biliverdin IX-α. Bilirubin-mixed isomers (MI)=93%
Bilirubin IX-α, and 6% associated Bilirubin isomers. Bilirubin
IX-α=>99% bilirubin IX-α. (With permission Zhu et al., 2010a see
original manuscript for further details.)
groups which folds the molecule into a hydrophobic “ridge–tile”
structure (Nogales and Lightner, 1995). The NS3/4A protease has
an unusually long and shallow active site groove that is quite atyp-
ical for serine activated proteases (Love et al., 1996). Presumably,
the active site accommodates the flat BV molecule to allow stable
occupation while the bulky hydrophobic BR fits poorly. Presently,
it is unclear which functional groups interact with the serine active
site triad and where potential allosteric sites may be located. How-
ever, these interactions appear important for future drug design
of tetrapyrroles as antiviral agents.
At first we attributed the antiviral activity of heme to its induc-
tion of HO-1 and rapid oxidation with liberation of free iron and
BV. However, direct testing of heme against the recombinant HCV
NS3/4A protease in the FRET assay has revealed that heme, like
BV, is also a direct protease inhibitor. Furthermore, some related
metalloprotoporphyrins (MPP) such as ZnPP, also showed potent
antiprotease and antiviral activities in vitro which occurred at quite
similar inhibitor concentrations (Figure 4; Zhu et al., 2011). Fur-
ther studies looking at relationships between tetrapyrrole struc-
ture, HCV protease binding affinity, and antiviral activity are
ongoing in our laboratory. However, as noted above, planar com-
pounds such as metal protoporphyrins appear to bind protease
tightly in contrast to folded structures such as bilirubin derivatives,
conjugated bilirubins, and mesoporphyrins (Zhu et al., 2010a).
Porphyrins with structures related to heme and ZnPP, such as
the meso derivative ZnMP, have also been shown to have antiviral
actions through HO-1 induction, however, with a more indirect
mechanism. Transcriptional activation of HO-1 depends, in part,
on Bach 1 a negative repressor of the HO-1 promoter region
(Ogawa et al., 2001; Kitamuro et al., 2003). ZnMP was shown to
induce the degradation of Bach 1 protein through increased pro-
teasome degradation thus alleviating HO-1 promoter repression,
facilitating HO-1 induction, and subsequent reduction of HCV
RNA in NS replicons (Hou et al., 2008). Furthermore, a follow up
study from the same group demonstrated that ZnMP could tar-
get HCV NS proteins such as NS5A for proteasomal degradation
through ubiquitination (Hou et al., 2010).
INDIRECT ANTI-HCV EFFECTS OF HEME AND DERIVATIVES
Other reasons for the antiviral activity of heme and related mole-
cules have also been investigated. Lehmann et al. (2010) reported
that BV induced type I interferon expression in replicon cells which
was accompanied by expression of interferon stimulated gene
products. While this study was the first to describe direct interac-
tion of an important natural tetrapyrrole with the innate immune
system, the mechanism is not yet clear (Lehmann et al., 2010). Pri-
mary induction of interferon by BV in vitro has not been reported
previously and appears contrary to the known anti-inflammatory
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FIGURE 4 | Disappearance of HCV RNA and HCV NS3/4A inhibition
with biliverdin, heme, or ZnPP. (A–C) HCV RNA was determined in
total RNA extracted from replicon cells incubated with the indicated
concentrations of tetrapyrrole for 48 h. Independent determinations of
the inhibitory activity of each tetrapyrrole for recombinant HCV NS3/4A
was determined by FRET analysis (Zhu et al., 2010a). Results are
means±SEM of six determinations per point. (With permission; Zhu
et al., 2011.)
character of BV and HO-1 induction. BV has been shown to induce
nuclear accumulation of biliverdin reductase which then decreases
nuclear NFkB in Hek293 cells (Gibbs and Maines, 2007; Gibbs
et al., 2010). The latter findings are consistent with an immunosup-
pressive role for BV (Ollinger et al., 2007) in contrast to the more
pro-inflammatory properties of heme (Gozzelino et al., 2010). On
the other hand, in other cell types such as human myeloid cells,
HO-1 induction was noted to be essential for IRF3 and NFkB acti-
vation and nuclear accumulation which are prerequisites for type
I interferon induction (Tzima et al., 2009; Kalliolias and Ivashkiv,
2010). HO-1 knockout mice demonstrated that HO-1 induction is
necessary for early phase activation of the innate immune sensing
pathways TRIF–IRF3 and RIG-I–IRF3 with Sendai virus for the
production of β-interferon and other primary response cytokines
(Tzima et al., 2009; Koliaraki and Kollias, 2011). It is not known
whether an HO-1 enzymatic product or a secondary mediator is
required for these activities or whether they occur in other cell
types such as hepatocytes. Nevertheless, these findings expand the
influences of HO-1 into innate immunity and potentially other
related pathways.
BV AND HEME CAN REVERSE HCV NS3/4A INHIBITION OF
TYPE I INTERFERON INDUCTION
As is typical of viral pathogens, the NS3/4A protease has extra viral
proteolytic activities that serve to increase the efficiency of viral
infection and evasion of host immune system. NS3/4A can cleave
pattern recognition receptors (PRR) or their interface adapter pro-
teins within type I interferon signaling pathways and thus disable
transcriptional induction of α and β interferon (Li et al., 2005b;
Meylan et al., 2005; Loo et al., 2006; Bode et al., 2007; Kalliolias and
Ivashkiv, 2010). The two best studied induction pathways likely
important for HCV responses are those that recognize intracellular
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double stranded (ds) RNA and include the Toll like receptor 3
(TLR3) and the Retinoic acid inducible gene-1 (RIG1) pathways.
HCV NS3/4A cleaves specific adapter proteins of both pathways
including TRIF of the TLR3 system and Cardiff of the RIG1 system
(Figure 5; Li et al., 2005b; Meylan et al., 2005; Bode et al., 2007).
Knowing that heme and other tetrapyrroles inhibit the HCV pro-
tease, we recently investigated whether these compounds would
restore type I interferon induction after disruption of interferon
signaling with the protease.
Clonal cell lines of Huh 7 such as Huh7.5 and Huh 515 are
known to have poor dsRNA and dsDNA innate immunity recog-
nition which is a likely reason that they are permissive for HCV
replication (Li et al., 2005a; Cheng et al., 2007). Consequently,
to evaluate the effects of heme on type I interferon signal-
ing, it was necessary to construct a reconstituted model system.
Hek293 cells were chosen because they are known to have rel-
atively intact innate immune recognition and high transfection
efficiency (Khvalevsky et al., 2007). We transfected dsRNA antigen
into Hek293 cells and 48 h later assessed interferon induction using
luciferase reporter gene constructs containing promoter regions
for β interferon. Transfection of dsRNA elicited robust induction
of type I interferon, however, this was clearly attenuated when cells
were co-transfected with NS3/4A expression vectors (Figure 6).
In contrast, incubation with heme or BV significantly restored
induction in the presence of protease and depending on protease
and substrate concentrations, this was nearly complete in some
cases (Figures 6A,B; Zhu et al., 2011). Additionally, restoration
of interferon induction in the presence of protease was sharply
accompanied by induction of interferon stimulated response gene
(ISRG) products such as OAS-1 as shown here (Figures 6C,D; Zhu
et al., 2011). Furthermore, we noted that BV or heme only controls
without protease, showed little ability to augment type I interferon
induction when incubated with cells either with or without dsRNA
antigen. This suggests that in the present system the tetrapyrroles
are unlikely to induce type I interferons as a primary antiviral
mechanism. Nevertheless, these data expand the capabilities of
heme and similar tetrapyrroles to promote beneficial effects for
the innate immune system.
HUMAN IMMUNODEFICIENCY VIRUS
Human Immunodeficiency virus is a human pathogenic RNA
retrovirus of the genus Lentivirus first identified in the early
1980s (Barresinoussi et al., 1983; Popovic et al., 1984) and found
worldwide. HIV is not a hepatotrophic virus, however as noted
FIGURE 5 | Schematic of HCV NS3/4A protease inhibition of innate
immune signaling pathways:TLR3 and RIG1. Double stranded RNA
(dsRNA) viruses or viruses with dsRNA intermediate activate innate
immune system signaling pathways for type I interferon induction
through binding to Pattern Recognition Receptors (PRR). For HCV, PRR
are associated with at least two major signaling pathways: TLR3 and
RIG1. Upon intracellular binding of dsRNA to associated adapter proteins
TRIF and CARDIFF, respectively, signaling is transmitted through complex
intermediate steps of recognition, binding, and phosphorylation leading
to activation of the transcriptional factors IRF3 and NFκB. The activated
nuclear transcription factors bind to type I interferon promoters and
induce α/β-interferon transcription. HCV NS3/4A protease is known to
cleave both TRIF and CARDIFF adapters thus crippling innate immune
antigen recognition and signaling for type I interferon induction. With
permission (Bode et al., 2007), see original review for terminology and
abbreviations.
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FIGURE 6 | Biliverdin and Heme can restore IFN promoter activation
and Interferon Stimulated Response Genes (ISRG) after interference
of IFN signaling with HCV NS3/4A. (A,B) HEK 293 cells were
transfected with dsRNA and vectors containing Type I IFN
promoter-luciferase construct and complete NS3/4A sequence plasmid
construct or control plasmid. Cells were then incubated with heme
(20µM) or Biliverdin (50µM) for 48 h. Cellular lysates were prepared and
assayed for interferon promoter activation using luciferase assay (Zhu
et al., 2010b). Each point is the mean of six determinations (two separate
cell culture incubations, and then three replicates for luciferase assay per
incubation). (C,D) Parallel experiments showing that heme and BV can
restore interferon stimulated response genes (ISRG) after inhibition with
NS3/4A protease. HEK 293 cells were transfected with dsRNA with or
without HCV NS3/4A plasmid then incubated with heme or BV for same
time and concentrations as (A,B) OAS-1 mRNA was measured using Real
Time RT-PCR. Each point is the mean of six determinations as described
for (A,B) **p< 0.01; *p<0.05; NS, not significant. (With permission Zhu
et al., 2011.)
previously, a high percentage of patients with HIV are co-infected
with HCV and/or HBV because they share common risk factors
for transmission (Quan et al., 1993; Zylberberg and Pol, 1996).
HIV co-infected patients, especially those with markedly depressed
CD4 T cell levels and AIDS, are known to have more aggressive
liver disease with increased incidence of cirrhosis as compared to
patients with controlled HIV or HCV/HBV monoinfection (Telfer
et al., 1994; Darby et al., 1997). Because of the global impact of
the AIDS pandemic in the 1980s a tremendous research effort has
been invested in drug discovery for an ever expanding list of HIV
targets. While mechanistic studies of HIV are not directly applic-
able to the hepatotrophic viruses per se, the large research effort
that developed model systems for anti-HIV drug design forged a
path that has facilitated drug discovery for hepatitis viruses.
The antiviral interactions of heme with HIV were investigated
early after the virus was discovered. These experiments established
that heme has the ability to inhibit reverse transcriptases (RT)
such as Rauschermurine leukemia virus RT (Tsutsui and Mueller,
1987). Ensuing work (Levere et al., 1991) showed that heme
administered alone or together with 3′-azido-3′-deoxythymidine
(AZT) was able to repress replication of HIV in human peripheral
blood lymphocytes and H9 cell lines. This activity was found for
both AZT-resistant and drug-sensitive HIV strains. Dose response
studies showed significant antiviral activity at physiological lev-
els of heme as low as 1µM and there was a clear, enhancing
effect of heme in combination with AZT. Additional work from
the same group demonstrated that heme was a non-competitive
inhibitor of HIV-1 RT in contrast to classical competitive inhibi-
tion with deoxythymidine triphosphates (Staudinger et al., 1996).
Some early structure-function relationships were also established
from testing of heme analogs and other more diverse MP struc-
tures. Interestingly, the protoporphyrin structure was found to
be crucial for anti-RT activity since metal meso derivatives were
inactive.
Argyris et al. (1999) then identified a unique non-nucleoside
inhibitory binding site for heme and putatively other MPs located
in the connection domain (region 398–407 aa residues) of HIV-
1 and 2 RT. The site was revealed through heme binding assays
matched to a phage-displayed 12 mer peptide library. Analysis of
the peptides that actively bound heme showed that, as a group,
they tended to be enriched in the aromatic amino acids Trp and
Tyr while Cys residues were completely absent. There was syn-
ergism for RT inhibition with the unique heme binding site and
another well-characterized non-nucleoside binding site located in
the p66 palm sub domain (BHAP; Argyris et al., 1999). The authors
speculated that the Tyr and Trp residues in this site of the enzyme
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facilitate heme binding through aromatic stacking with the planar
porphyrin ring, while the propionyl and vinyl side chains anchor
the holo heme.
The linear tetrapyrrole oxidation product of heme, biliverdin
(BV), and its reduced derivative, bilirubin (BR) have also been
reported to directly inhibit the HIV aspartic acid activated pro-
tease (McPhee et al., 1996). Using assays of recombinant HIV-1
protease, BV and BR showed nearly equal K i values of about
1µM for HIV-1, 2, and simian immunodeficiency virus proteases.
Related tetrapyrroles showed some antiprotease activity but at
much higher concentrations. It should be emphasized that the
inhibitory activities of BR and BV were noted to take place at
near physiological concentrations of BR (17µM is 1.0 mg/dl).
Additionally, several synthetic boronated porphyrins also showed
competitive inhibition of the HIV protease with K i’s in the mid
nanomolar range (Decamp et al., 1992).
ANTI-HIV EFFECTS OF HO-1 INDUCTION ON HIV
More recent work on the effects of heme on HIV replication
demonstrated that heme also elicits antiviral activity through
induction of HO-1 (Devadas and Dhawan, 2006). Heme was
antiviral in vitro in a dosage dependent manner and elicited more
than a 90% reduction of intracellular HIV in monocytes or T cells
and was even active on drug resistant strains. While the heme
antiviral targets that enabled these data were not specifically pur-
sued, we can assume that heme likely worked through inhibition of
viral uptake, RT inhibition, and/or inhibition of the HIV protease
through heme oxidation products BV and BR as discussed above.
An important point of this study is that it established that heme
can attenuate viral levels in vivo. Intraperitoneal administration
of heme attenuated HIV replication in humanized non-obese dia-
betic SCID mice carrying infected human PBMCs (Devadas and
Dhawan, 2006).
HEPATITIS B VIRUS
Hepatitis B virus is the most common chronic viral pathogen
worldwide. The virus is a member of the hepadnavirus family and
is one of the smallest known pathogenic human DNA viruses of
about 3.2 kb. The virus replicates through a unique pre-genomic
(pg) mRNA intermediate made by host nuclear enzymes which
is then reverse transcribed into genomic DNA using a unique
hepadnaviral reverse transcriptase. The reverse transcriptase of
HBV shares a number of active site and substrate features with the
HIV RT resulting in inhibitory drug overlap with HIV. However,
hepadnaviral DNA synthesis employs a unique protein priming
method for initiation of replication from pg RNA. The RT protein
acts as both a protein primer and polymerase through interac-
tion with a viral RNA structure (60 nucleotides) called ∈ at the
5′ end of pg RNA. This complex facilitates origin of reverse tran-
scription, packaging, and replication fidelity (Pollack and Ganem,
1994; Tavis et al., 1994; Wang et al., 1994). In contrast to both HIV
and HCV, replication and assembly of HBV occurs without a viral
protease.
As compared to HIV and HCV, interactions of heme and heme
oxygenase-1 with HBV have not been extensively evaluated. Nev-
ertheless, HO-1 appears to be upregulated in response to chronic
HBV infection as shown by immunohistochemical labeling of
human liver samples (Abdalla et al., 2004). In a transgenic mouse
model of acute and chronic HBV infection, Protzer et al. (2007)
showed that induction of HO-1 attenuated viral replication as
determined by reduced levels of HBV core protein. In addition
to virucidal activity, HO-1 induction also led to reduced liver
injury and hepato protective effects. The authors suggested that
HO-1 induction worked posttranscriptionally to reduce the sta-
bility of HBV core protein (Protzer et al., 2007). Furthermore the
combination of hepato protective effects from cellular injury and
virucidal capabilities of HO-1 induction suggest additional bene-
fits for potential antiviral drugs that could be designed using this
important pathway.
Because heme was shown to have a specific inhibitory binding
site on the HIV RT, we might predict that a similar interaction
would occur with HBV. While recent evidence indicates that HBV
replication is indeed inhibited by heme in vitro, at least one mech-
anism is decidedly different (Lin and Hu, 2008). Heme blocked the
interaction of the RT protein with the ∈ segment of pg RNA, thus
inhibiting the protein priming step of HBV replication. The heme
binding site was localized to the N-terminal domain of the RT
protein which is unique to hepadnaviral RT. In addition to heme,
protoporphyrin free base and biliverdin were also active. While
further studies of viral resistance, ligand specificity, and mecha-
nism of these interactions need to be explored, these data suggest
that similar compounds could be employed as either primary or
adjunct therapy with nucleoside analogs for patients with chronic
HBV infection.
FINAL CONSIDERATIONS
In spite of development of new and improved antiviral agents
for HIV, HCV and HBV, there is a persistent and urgent need for
new treatment modalities as well as combination therapies. Nearly
all compounds developed against these pathogens have associated
problems with toxicity, viral resistance, and selectivity (De Clercq,
2007; Firpi and Nelson, 2007; Zoulim, 2011) which makes ongoing
discovery of new antivirals with improved clinical spectrum and
versatility necessary.
Table 1 summarizes the various sites of antiviral activity of the
precursors and products of the heme oxygenase-1 system for all
three viruses. It is apparent that the viral targets for heme are quite
similar among the viruses in spite of viral diversity. All three viruses
are inhibited by HO-1 induction and heme targets both HBV and
HIV RT. Interestingly, however, heme RT inhibition occurs at dif-
ferent relative sites on the respective enzymes. Furthermore, heme,
BV and BR inhibit both HIV and HCV proteases, in spite of the
fact that the proteases differ markedly in primary structure, cat-
alytic sites, and reaction mechanisms (Wlodawer et al., 1989; Love
et al., 1996; Yan et al., 1998; Brik and Wong, 2003). Finally, HO-
1 induction offers protection from oxidative injury in HBV and
HCV infection thus suggesting additional benefits against oxida-
tive induced tissue injury that is considered to be a primary chronic
disease mechanism leading to hepatic injury and fibrosis (Lieber,
1997; Lee et al., 2004; Qadri et al., 2004; Seronello et al., 2007).
Collectively, these findings indicate that heme and related por-
phyrins clearly should be considered for further in vivo transla-
tional studies, especially in suitable animal models and patient
pilot trials, at least for proof-of-concept. The ability to inhibit
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Table 1 | Activities of heme and related agents for HCV, HBV, and HIV.
Virus Agent Mechanism studied Reference
HCV BV Anti-NS3/4A protease Zhu et al. (2010a)
BV Type I interferon induction Lehmann et al. (2010)
Heme Anti-NS3/4A protease Zhu et al. (2010a)
Heme HO-1 induction Shan et al. (2007), Zhu et al. (2008)
ZnMP HO-1 induction and Bach 1 inhibition Hou et al. (2008)
ZnMP Ubiquitination of NS5A Hou et al. (2010)
Fe Antipolymerase Fillebeen et al. (2005)
Fe Decreased HCV replication Yuasa et al. (2006), Zhu et al. (2010a)
Fe HO-1 induction Hou et al. (2009)
Zn Decreased viral replication Yuasa et al. (2006)
HO-1 enzyme Enzyme overexpression Zhu et al. (2008)
HBV Heme Anti-reverse transcriptase Lin and Hu (2008)
HO-1 induction Protzer et al. (2007)
HIV BV/BR Anti-HIV protease McPhee et al. (1996)
Synthetic porphyrins Anti-HIV protease Decamp et al. (1992)
Heme/MPs Anti-reverse transcriptase Levere et al. (1991), Staudinger et al. (1996), Argyris et al. (1999)
HO-1 induction HO-1 induction Devadas and Dhawan (2006)
MPs Gp120 inhibition Song et al. (1997)
multiple viral target sites on different viruses indicates that these
compounds would be also useful for patients with dual or even
triple infections. Co-infected patients are a serious problem world-
wide and invariably present with more severe medical disease,
aggressive hepatitis, and a number of treatment dilemmas (den
Brinker et al., 2000; Koziel and Peters, 2007; Zhou et al., 2011).
Considering the antiviral fidelity of heme and products of the
heme oxygenase system it is an open question as to the why these
agents have not been developed further for antiviral therapy. Heme
is proven to be efficacious for use in vivo for acute porphyria and
is usually well tolerated. Further in vivo studies should focus on
evaluation of porphyrin based antivirals with oral bioavailabil-
ity, safety, and attractive pharmacodynamic capabilities to expand
their use for HCV, HIV, and HBV infections.
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